Related Experiment Videos

Isolation and characterization of a membrane-attack-complex-inhibiting protein present in human serum and other

M J Watts1, J R Dankert, E P Morgan

  • 1Department of Medical Biochemistry, University of Wales College of Medicine, Cardiff, U.K.

The Biochemical Journal
|January 15, 1990
PubMed

Insights

Researchers identified a membrane-attack-complex-inhibiting protein (MIP) in human body fluids. This protein, identical to the erythrocyte-derived MIP, plays a role in complement activation and erythrocyte lysis.

Area of Science:

  • Immunology
  • Complement system biology

Background:

  • A membrane-attack-complex-inhibiting protein (MIP) was previously isolated from human erythrocyte membranes.
  • Polyclonal antibodies against erythrocyte MIP were generated.

Purpose of the Study:

  • To identify and characterize MIP in human body fluids.
  • To develop a method for quantifying MIP in plasma, urine, and cerebrospinal fluid.
  • To investigate the role of plasma MIP in complement activation.

Main Methods:

  • Immunochemical identification of MIP in plasma, urine, saliva, and cerebrospinal fluid.
  • Immunoaffinity chromatography for plasma MIP isolation.
  • SDS/polyacrylamide-gel electrophoresis for molecular mass determination.
  • Generation of monoclonal antibodies and development of a two-site enzyme-linked immunosorbent assay (ELISA).

Main Results:

  • A protein immunochemically identical to erythrocyte MIP was found in plasma, urine, saliva, and cerebrospinal fluid.
  • Plasma MIP has a molecular mass of 55 kDa (non-reduced) and 65 kDa (reduced).
  • A sensitive ELISA was established for MIP quantification in various body fluids.
  • Plasma MIP deposition on erythrocyte membranes during complement activation is C8-dependent.
  • Depletion of plasma MIP enhanced hemolytic activity against heterologous erythrocytes.

Conclusions:

  • MIP is present in various human body fluids and is immunochemically identical to the erythrocyte-derived protein.
  • Plasma MIP is involved in the regulation of complement-mediated lysis.
  • The developed ELISA allows for the quantification of MIP in clinical samples.

Related Concept Videos